Inhibition of human ether-a-go-go-related gene potassium channels by α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin

[1]  H. Katus,et al.  Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. , 2003, Cardiovascular research.

[2]  H. Katus,et al.  Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  H. Katus,et al.  Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. , 2003, Cardiovascular research.

[4]  J. Mitcheson.  Drug binding to HERG channels: evidence for a ‘non‐aromatic’ binding site for fluvoxamine , 2003, British journal of pharmacology.

[5]  H. Katus,et al.  Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  Hugo A Katus,et al.  The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.

[7]  N. Kyprianou.  Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. , 2003, The Journal of urology.

[8]  E. Wanke,et al.  Cell Cycle-dependent Expression of HERG1 and HERG1B Isoforms in Tumor Cells* , 2003, The Journal of Biological Chemistry.

[9]  R. Piñeiro,et al.  Doxazosin Induces Apoptosis in Cardiomyocytes Cultured In Vitro by a Mechanism That Is Independent of &agr;1-Adrenergic Blockade , 2003, Circulation.

[10]  Baofeng Yang,et al.  HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. , 2002, Cancer research.

[11]  E. Newell,et al.  Functional Up-regulation of HERG K+ Channels in Neoplastic Hematopoietic Cells* , 2002, The Journal of Biological Chemistry.

[12]  Stanley Nattel,et al.  A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? , 2002, The Journal of physiology.

[13]  Dierk Thomas,et al.  The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.

[14]  N. Kyprianou,et al.  Quinazoline-derived α1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α1-Adrenoceptor-independent Action , 2002 .

[15]  E. Crawford,et al.  Terazosin, doxazosin, and prazosin: current clinical experience. , 2001, Urology.

[16]  T. McDonald,et al.  HERG K+ Channel Activity Is Regulated by Changes in Phosphatidyl Inositol 4,5-Bisphosphate , 2001, Circulation research.

[17]  A. Brown,et al.  High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. , 2001, The Journal of pharmacology and experimental therapeutics.

[18]  S. Kathöfer,et al.  Antiarrhythmic drug carvedilol inhibits HERG potassium channels. , 2001, Cardiovascular research.

[19]  E. Wanke,et al.  HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium , 2000, British Journal of Cancer.

[20]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Kyprianou,et al.  Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. , 2000, Cancer research.

[22]  P. Kang,et al.  Apoptosis and heart failure: A critical review of the literature. , 2000, Circulation research.

[23]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[24]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[25]  M. Jiang,et al.  Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  S. Viskin.  Long QT syndromes and torsade de pointes , 1999, The Lancet.

[27]  W. Kübler,et al.  Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A* , 1999, The Journal of Biological Chemistry.

[28]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[29]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[30]  W. Kübler,et al.  Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  M. Gaffney,et al.  Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. , 1999, Urology.

[32]  M. Lazdunski,et al.  HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. , 1998, Molecular pharmacology.

[33]  L. Bianchi,et al.  herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? , 1998, Cancer research.

[34]  W. Wonderlin,et al.  Potassium Channels, Proliferation and G1 Progression , 1996, The Journal of Membrane Biology.

[35]  Pool Jl,et al.  DOXAZOSIN: A NEW APPROACH TO HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA , 1996, The British journal of clinical practice.

[36]  R. Ruffolo,et al.  Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. , 1996, The Journal of pharmacology and experimental therapeutics.

[37]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[38]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Grimm,et al.  alpha 1-antagonists in the treatment of hypertension. , 1989, Hypertension.

[40]  S. Umemura,et al.  Antihypertensive Effects and Pharmacokinetics of Single and Consecutive Administration of Doxazosin in Patients with Mild to Moderate Essential Hypertension , 1987, Journal of cardiovascular pharmacology.

[41]  P. Meredith,et al.  Pharmacokinetic overview of doxazosin. , 1987, The American journal of cardiology.

[42]  R. Sonders.  Pharmacokinetics of terazosin. , 1986, The American journal of medicine.

[43]  S. E. Patterson.  Terazosin kinetics after oral and intravenous doses , 1985, Clinical pharmacology and therapeutics.

[44]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[45]  D. Shen,et al.  Alpha adrenoceptor blockade with oral prazosin , 1981, Clinical pharmacology and therapeutics.

[46]  M. Safar,et al.  Clinical Pharmacology of Prazosin in Hypertensive Patients with Chronic Renal Failure , 1981, Journal of cardiovascular pharmacology.

[47]  P. Jaillon.  Clinical Pharmacokinetics of Prazosin , 1980, Clinical pharmacokinetics.

[48]  M. Michel,et al.  Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. , 1998, British journal of clinical pharmacology.